Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

We are currently facing an issue in receiving the NSE feed. Hence the stock prices are not updated. We are working on fixing this at the earliest. We regret the inconvenience caused.

Small cap and Mid cap in favour
Tue, 22 Oct 01:30 pm

Indian markets continued to trade weak during the post noon trading session. Sectoral indices are trading mixed. Stocks from oil and gas and consumer durables are witnessing maximum selling pressure, while stocks from power and IT sectors are leading the pack of gainers.

BSE-Sensex is down by 50 points and NSE-Nifty is trading down by 12 points. While BSE Mid Cap is trading up by 0.63%, BSE Mid Cap index is trading up by 0.97%.The rupee is trading at 61.67 to the US dollar.

As per a leading financial daily, majority of the states have opposed the inclusion of petroleum products and liquor in the framework of Goods and Services Tax (GST) regime. Recently, the empowered committee of State Finance Ministers had introduced the revised draft of Constitutional Amendment Bill for the introduction of the GST bill. Some states have also expressed their disapproval for the inclusion of the entry tax in the GST fold. Consequently the Empowered Committee could not complete its discussion on the revised bill that has been deferred till the next meeting. The implementation of the new indirect tax has been delayed for quite some time now as a result of disagreements between the Centre and States over the tax structure.

Indian pharma stocks are trading mixed. Indoco Remedies and JB chemicals are among the leading gainers, while Wockhardt Ltd and Natco pharma are top losers. Lupin Ltd, announced that the company has received approval for its new drug application for Antara capsules with strength 30mg and 90mg from the US regulator, USFDA. The company would commence the marketing of this drug shortly. Lupin is already selling Antara brand of 43mg and 130mg strength. The said drug, generically known as fenofibrate is prescribed for adjunct treatment of hypercholesterolemia (high blood cholesterol), mixed dyslipidemia and hyper-triglyceridemia (high triglycerides). In our view as various generics of fenofibrate are already available, this launch will not fetch material upside to the company. Lupin was trading up by 0.6% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Small cap and Mid cap in favour". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.